KRAS and non-small cell lung carcinoma: Divarasib seems to demonstrate more favorable responses and extended progression-free survival rates in individuals diagnosed with either NSCLC or CRC than these reported with current single-agent KRAS G12C inhibitors (NCT04449874) [60].